RxDoctor Payments Data

Rebecca Byrd, MD

Internal Medicine · Birmingham, ALNPI 1073616629

Payments from drug & device makers

$11,119in general payments, 2019–2025

Across 614 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$929
  • Johnson & Johnson$864
  • AstraZeneca$717
  • AbbVie$673
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$11,105100%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,119 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$124,060
Medicare patients
362
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$206,922
JardianceEmpagliflozin108$114,958
MounjaroTirzepatide82$89,781
EliquisApixaban105$75,187
JanuviaSitagliptin Phosphate77$73,665
FarxigaDapagliflozin Propanediol48$51,001
XareltoRivaroxaban29$36,797
RybelsusSemaglutide28$35,920
TrulicityDulaglutide27$27,057
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$15,166
Breo ElliptaFluticasone/Vilanterol28$12,803
LinzessLinaclotide11$11,131
Rosuvastatin Calcium447$11,031
Levothyroxine Sodium545$7,983
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$7,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,101$242,842185 claims
Lilly USA, LLCMounjaro, Trulicity, Lyumjev$929$120,481123 claims
Boehringer IngelheimJardiance$340$114,958108 claims
PfizerEliquis, Premarin$1,444$78,118121 claims
MerckJanuvia$250$73,66577 claims
AstraZenecaFarxiga$717$51,00148 claims
Johnson & JohnsonXarelto, Invokana$864$43,21540 claims
AbbVieLinzess, Synthroid$673$17,47086 claims
GSKBreo Ellipta$369$12,80328 claims
Sumitomo Pharma America, Inc.Gemtesa$53$6,21312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →